{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:19:56Z","timestamp":1740143996257,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010377","name":"National Institute for Health and Care Excellence","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010377","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40258-021-00701-0","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T02:03:12Z","timestamp":1640743392000},"page":"305-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-9902","authenticated-orcid":false,"given":"Ruth Louise","family":"Poole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7229-5109","authenticated-orcid":false,"given":"Megan","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2470-9746","authenticated-orcid":false,"given":"Helen","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4226-4349","authenticated-orcid":false,"given":"Tosin","family":"Oladapo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Brookfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7450-5923","authenticated-orcid":false,"given":"Rhys","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,29]]},"reference":[{"issue":"5","key":"701_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF03261863","volume":"10","author":"B Campbell","year":"2012","unstructured":"Campbell B, Campbell M. NICE medical technologies guidance: a novel and rigorous methodology to address a new health technology assessment challenge. Appl Health Econ Health Policy. 2012;10(5):295\u20137.","journal-title":"Appl Health Econ Health Policy"},{"key":"701_CR2","unstructured":"National Institute for Health and Care Excellence. Medical technologies guidance. London: NICE; 2021. Available at: https:\/\/www.nice.org.uk\/About\/What-we-do\/Our-Programmes\/NICE-guidance\/NICE-medical-technologies-guidance. Accessed 14 May 2021."},{"key":"701_CR3","doi-asserted-by":"crossref","unstructured":"Poole RL, Dale M, Morgan H, Ryczek E, Cohen B, Carolan-Rees G. Axonics sacral neuromodulation system for treating refractory overactive bladder (external assessment report). 2019. Available at: https:\/\/www.nice.org.uk\/guidance\/mtg50\/documents\/supporting-documentation-2. Accessed 21 Mar 2021.","DOI":"10.1007\/s40258-021-00701-0"},{"key":"701_CR4","unstructured":"National Institute for Health and Care Excellence. Axonics sacral neuromodulation system for treating refractory overactive bladder. London: NICE; Sep 2020. (Medical technologies guidance [MTG50]). Available at: https:\/\/www.nice.org.uk\/guidance\/mtg50. Accessed 21 Mar 2021."},{"key":"701_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/JU.0000000000000458","volume":"203","author":"R McCrery","year":"2020","unstructured":"McCrery R, Lane F, Benson K, et al. Treatment of urinary urgency incontinence using a rechargeable SNM system: 6-month results of the ARTISAN-SNM study. J Urol. 2020;203:185\u201392.","journal-title":"J Urol"},{"key":"701_CR6","doi-asserted-by":"publisher","unstructured":"Lane F, McCrery R, Taylor C, et al. Treatment of urinary urgency incontinence with the Axonics miniaturised, rechargeable SNM system: clinical outcomes of the ARTISAN-SNM pivotal study. Int Urogynecol J. 2019;30:1\u201329. https:\/\/doi.org\/10.1007\/s00192-019-04123-4. In: AUGS\/IUGA Scientific Meeting: Abstracts of Long Oral Presentations, IUGA 44th Annual Meeting\u2014Nashville, TN, USA, September 24\u201328, 2019.","DOI":"10.1007\/s00192-019-04123-4"},{"key":"701_CR7","unstructured":"Benson K, McCrery R, Taylor C, et al. One-year outcomes of the Axonics system for treatment of urinary urgency incontinence. SUFU 2020 Winter Meeting abstract. Podium #29: Available at: https:\/\/sufuorg.com\/docs\/meetings\/sufu2002\/2020-program-book-abstracts.aspx. Accessed 21 Mar 2021. (An early draft of this abstract was submitted by the company to NICE, with Lane listed as the first author)."},{"issue":"S2","key":"701_CR8","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1002\/nau.23465","volume":"37","author":"B Blok","year":"2018","unstructured":"Blok B, Van Kerrebroeck P, de Wachter S, et al. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol Urodyn. 2018;37(S2):S9\u201316.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"701_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/nau.23892","volume":"38","author":"B Blok","year":"2019","unstructured":"Blok B, Van Kerrebroeck P, de Wachter S, et al. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study. Neurourol Urodyn. 2019;38(2):689\u201395.","journal-title":"Neurourol Urodyn"},{"key":"701_CR10","unstructured":"Blok B, de Wachter S, Ruffion A et al. Two years outcomes of the treatment of overactive bladder with the miniaturized, rechargeable Axonics system. International Continence Society. 2019 [abstract and e-poster]. Available at: https:\/\/www.ics.org\/2019\/abstract\/158. Accessed 21 Mar 2021."},{"issue":"Suppl 2","key":"701_CR11","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1002\/nau.23476","volume":"37","author":"B Blok","year":"2018","unstructured":"Blok B, Van Kerrebroeck P, de Wachter S, et al. Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol Urodyn. 2018;37(Suppl 2):S17\u201322.","journal-title":"Neurourol Urodyn"},{"key":"701_CR12","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/nau.24376","volume":"39","author":"K Benson","year":"2020","unstructured":"Benson K, McCrery R, Taylor C, et al. One-year outcomes of the ARTISAN-SNM study with the Axonics system for the treatment of urinary urgency incontinence. Neurourol Urodyn. 2020;39:1482\u20138.","journal-title":"Neurourol Urodyn"},{"key":"701_CR13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/nau.24317","volume":"39","author":"B Blok","year":"2020","unstructured":"Blok B, Van Kerrebroeck P, de Wachter S, et al. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system. Neurourol Urodyn. 2020;39:1108\u201314.","journal-title":"Neurourol Urodyn"},{"key":"701_CR14","unstructured":"Bangel KA, Cole H, Drinnan M. MT417 Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder: external assessment centre technical assessment report. Newcastle: EAC; 2020. Available at: https:\/\/www.nice.org.uk\/guidance\/mtg50\/documents\/supporting-documentation-2. Accessed 21 Mar 2021."},{"key":"701_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10198-015-0737-2","volume":"17","author":"N Freemantle","year":"2016","unstructured":"Freemantle N, Khalaf K, Loveman C, et al. Onabotuliniumtoxin A in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales. Eur J Health Econ. 2016;17:911\u201321.","journal-title":"Eur J Health Econ"},{"key":"701_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/nau.23008","volume":"36","author":"KL Noblett","year":"2017","unstructured":"Noblett KL, Dmochowski RR, Vasavada SP, Garner AM, Liu S, Pietzsch JB. Cost profiles and budget impact of rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome. Neurourol Urodyn. 2017;36:727\u201333.","journal-title":"Neurourol Urodyn"},{"key":"701_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/nau.22707","volume":"35","author":"K Noblett","year":"2016","unstructured":"Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2016;35:246\u201351.","journal-title":"Neurourol Urodyn"},{"key":"701_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/nau.22618","volume":"34","author":"B Chughtai","year":"2015","unstructured":"Chughtai B, Sedrakyan A, Issacs A, Lee R, Te A, Kaplan S. Long term safety of sacral nerve modulation in Medicare beneficiaries. Neurourol Urodyn. 2015;34:659\u201363.","journal-title":"Neurourol Urodyn"},{"key":"701_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/nau.22294","volume":"32","author":"AP Cameron","year":"2013","unstructured":"Cameron AP, Anger JT, Madison R, et al. Battery explantation after sacral neuromodulation in the Medicare population. Neurourol Urodyn. 2013;32:238\u201341.","journal-title":"Neurourol Urodyn"},{"key":"701_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/1553350613485303","volume":"20","author":"AM Suskind","year":"2013","unstructured":"Suskind AM, Dunn RL, Kaufman SR, et al. Understanding the dissemination of sacral neuromodulation. Surg Innov. 2013;20:625\u201330.","journal-title":"Surg Innov"},{"key":"701_CR21","unstructured":"NHS Improvement. National Schedule of Reference Costs 2017\/18. Available at: https:\/\/webarchive.nationalarchives.gov.uk\/20200501111106\/https:\/\/improvement.nhs.uk\/resources\/reference-costs\/. Accessed 21 Mar 2021"},{"key":"701_CR22","unstructured":"NHS Supply Chain. Available at: https:\/\/www.supplychain.nhs.uk\/. Accessed Sep 2019."},{"key":"701_CR23","doi-asserted-by":"crossref","unstructured":"National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. London: NICE; Apr 2019, updated June 2019 (NICE guideline [NG123]). Available at: https:\/\/www.nice.org.uk\/guidance\/ng123. Accessed 21 Mar 2021.","DOI":"10.1111\/bju.14763"},{"key":"701_CR24","unstructured":"National Institute for Health and Care Excellence. Lower urinary tract symptoms in men: management. London: NICE; May 2010, updated June 2015 (Clinical guideline [CG97]). Available at: https:\/\/www.nice.org.uk\/guidance\/cg97. Accessed 21 Mar 2021."},{"key":"701_CR25","unstructured":"National Institute for Health and Care Excellence. Axonics sacral neuromodulation system for treating refractory overactive bladder: resource impact statement. Available at: https:\/\/www.nice.org.uk\/guidance\/mtg50\/resources\/resource-impact-statement-8838383005. Accessed 21 Mar 2021."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-021-00701-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-021-00701-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-021-00701-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:13:59Z","timestamp":1650536039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-021-00701-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,29]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1007\/s40258-021-00701-0","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"type":"print","value":"1175-5652"},{"type":"electronic","value":"1179-1896"}],"subject":[],"published":{"date-parts":[[2021,12,29]]},"assertion":[{"value":"8 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RLP, MD, HM, RB, and TO contributed to the preparation of this manuscript. RM reviewed the article, and can act as a guarantor for the overall content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"RLP, MD and RM are NHS employees, which has a financial interest in the guidance on which this project is based. HM is a Cardiff University employee and has no conflicts of interest to declare. RB and TO are NICE employees and had no role in the production of the assessment report but contributed to the preparation of this manuscript. This summary of the Medical Technology Guidance was produced following publication of the final guidance report. The article has not been externally peer reviewed by Applied Health Economics and Health Policy but has been reviewed externally by NICE. Cedar was funded by the NICE MTEP for their work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"National Institute for Health and Care Excellence (External Assessment Centre contract).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}